Efficacy and safety of secukinumab for the treatment of severe ABCA12 deficiency‐related ichthyosis in a child

• Váldodahkkit: J. Yogarajah (Dahkki), C. Gouveia (Dahkki), J. Iype (Dahkki), S. Häfliger (Dahkki), A. Schaller (Dahkki), J.M. Nuoffer (Dahkki), M. Fux (Dahkki), M. Gautschi (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Wiley, 2021-06-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Summary Background Patients with severe autosomal recessive congenital ichthyosis (ARCI) show a T helper 17/interleukin 17 (Th17/IL17) skewing in their skin and serum, resembling the inflammatory profile of psoriatic patients. Secukinumab, an IL‐17A inhibitor, has shown clinical efficacy in patients...